<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id>
<journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id>
<journal-title-group>
<journal-title>Pharmaceuticals</journal-title>
</journal-title-group>
<issn pub-type="epub">1424-8247</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31623237</article-id>
<article-id pub-id-type="pmc">6958487</article-id>
<article-id pub-id-type="doi">10.3390/ph12040156</article-id>
<article-id pub-id-type="publisher-id">pharmaceuticals-12-00156</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>C3orf70 Is Involved in Neural and Neurobehavioral Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ashikawa</surname>
<given-names>Yoshifumi</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceuticals-12-00156">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shiromizu</surname>
<given-names>Takashi</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceuticals-12-00156">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miura</surname>
<given-names>Koki</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceuticals-12-00156">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Adachi</surname>
<given-names>Yuka</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceuticals-12-00156">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matsui</surname>
<given-names>Takaaki</given-names>
</name>
<xref ref-type="aff" rid="af2-pharmaceuticals-12-00156">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bessho</surname>
<given-names>Yasumasa</given-names>
</name>
<xref ref-type="aff" rid="af2-pharmaceuticals-12-00156">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8213-383X</contrib-id>
<name>
<surname>Tanaka</surname>
<given-names>Toshio</given-names>
</name>
<xref ref-type="aff" rid="af3-pharmaceuticals-12-00156">3</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1901-8799</contrib-id>
<name>
<surname>Nishimura</surname>
<given-names>Yuhei</given-names>
</name>
<xref ref-type="aff" rid="af1-pharmaceuticals-12-00156">1</xref>
<xref ref-type="corresp" rid="c1-pharmaceuticals-12-00156">*</xref>
</contrib>
</contrib-group>
<aff id="af1-pharmaceuticals-12-00156"><label>1</label>Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; <email>thegracioso1113@gmail.com</email> (Y.A.); <email>tshiromizu@doc.medic.mie-u.ac.jp</email> (T.S.); <email>318090@m.mie-u.ac.jp</email> (K.M.); <email>319m001@m.mie-u.ac.jp</email> (Y.A.)</aff>
<aff id="af2-pharmaceuticals-12-00156"><label>2</label>Gene Regulation Research, Graduate School of Biological Sciences, Nara Institute of Science and Technology, Takayama, Nara 630-0192, Japan; <email>matsui@bs.naist.jp</email> (T.M.); <email>ybessho@bs.naist.jp</email> (Y.B.)</aff>
<aff id="af3-pharmaceuticals-12-00156"><label>3</label>Department of Systems Pharmacology, Mie University Graduate School of Medicine, Tsu, Mie 514-8507, Japan; <email>tanaka@doc.medic.mie-u.ac.jp</email></aff>
<author-notes>
<corresp id="c1-pharmaceuticals-12-00156"><label>*</label>Correspondence: <email>yuhei@doc.medic.mie-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>10</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2019</year>
</pub-date>
<volume>12</volume>
<issue>4</issue>
<elocation-id>156</elocation-id>
<history>
<date date-type="received">
<day>10</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>10</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© 2019 by the authors.</copyright-statement>
<copyright-year>2019</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Neurogenesis is the process by which undifferentiated progenitor cells develop into mature and functional neurons. Defects in neurogenesis are associated with neurodevelopmental and neuropsychiatric disorders; therefore, elucidating the molecular mechanisms underlying neurogenesis can advance our understanding of the pathophysiology of these disorders and facilitate the discovery of novel therapeutic targets. In this study, we performed a comparative transcriptomic analysis to identify common targets of the proneural transcription factors Neurog1/2 and Ascl1 during neurogenesis of human and mouse stem cells. We successfully identified <italic>C3orf70</italic> as a novel common target gene of Neurog1/2 and Ascl1 during neurogenesis. Using in situ hybridization, we demonstrated that <italic>c3orf70a</italic> and <italic>c3orf70b</italic>, two orthologs of <italic>C3orf70</italic>, were expressed in the midbrain and hindbrain of zebrafish larvae. We generated <italic>c3orf70</italic> knockout zebrafish using CRISPR/Cas9 technology and demonstrated that loss of <italic>c3orf70</italic> resulted in significantly decreased expression of the mature neuron markers <italic>elavl3</italic> and <italic>eno2</italic>. We also found that expression of <italic>irx3b</italic>, a zebrafish ortholog of <italic>IRX3</italic> and a midbrain/hindbrain marker, was significantly reduced in <italic>c3orf70</italic> knockout zebrafish. Finally, we demonstrated that neurobehaviors related to circadian rhythm and altered light–dark conditions were significantly impaired in <italic>c3orf70</italic> knockout zebrafish. These results suggest that C3orf70 is involved in neural and neurobehavioral development and that defects in C3orf70 may be associated with midbrain/hindbrain-related neurodevelopmental and neuropsychiatric disorders.</p>
</abstract>
<kwd-group>
<kwd>neurogenesis</kwd>
<kwd>neurobehavior</kwd>
<kwd>zebrafish</kwd>
<kwd>comparative transcriptome analysis</kwd>
<kwd>gene coexpression network</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-pharmaceuticals-12-00156" sec-type="intro">
<title>1. Introduction</title>
<p>Neurogenesis is the process by which undifferentiated progenitor cells, including embryonic and induced pluripotent stem cells, or previously differentiated somatic cells, develop into mature and functional neurons. Defects in neurogenesis are associated with neurodevelopmental disorders, such as autism [<xref ref-type="bibr" rid="B1-pharmaceuticals-12-00156">1</xref>,<xref ref-type="bibr" rid="B2-pharmaceuticals-12-00156">2</xref>,<xref ref-type="bibr" rid="B3-pharmaceuticals-12-00156">3</xref>] and intellectual disability [<xref ref-type="bibr" rid="B4-pharmaceuticals-12-00156">4</xref>,<xref ref-type="bibr" rid="B5-pharmaceuticals-12-00156">5</xref>], as well as adolescent and adult-onset neuropsychiatric disorders, such as major depression [<xref ref-type="bibr" rid="B6-pharmaceuticals-12-00156">6</xref>,<xref ref-type="bibr" rid="B7-pharmaceuticals-12-00156">7</xref>] and schizophrenia [<xref ref-type="bibr" rid="B2-pharmaceuticals-12-00156">2</xref>,<xref ref-type="bibr" rid="B8-pharmaceuticals-12-00156">8</xref>]. Therefore, elucidating the molecular mechanisms underlying neurogenesis can advance our understanding of the pathophysiology of these neurodevelopmental and neuropsychiatric disorders and may lead to the discovery of novel therapeutic targets.</p>
<p>Neurogenesis is a multi-step process involving (i) patterning of cells with neurogenic potential, which can be spread over the entire neuroectoderm or restricted to a particular domain; (ii) patterning of neural progenitors that arise within the neuroectoderm; (iii) asymmetric cell division of neural progenitor cells, which renews progenitor cells and produces a daughter cell that differentiates into a neuron or an intermediate progenitor; and (iv) movement of neural progenitors, such as integration within the surface neuroepithelium and internalization via delamination, ingression, or invagination [<xref ref-type="bibr" rid="B9-pharmaceuticals-12-00156">9</xref>].</p>
<p>Proneural proteins are a small group of basic-loop-helix (bHLH) transcription factors that include Achaete-scute family bHLH transcription factor 1 (Ascl1) and Neurogenin 1 and 2 (Neurog1/2). Expression of these proneural proteins is required to confer a neural fate on progenitor cells in the developing nervous system [<xref ref-type="bibr" rid="B10-pharmaceuticals-12-00156">10</xref>,<xref ref-type="bibr" rid="B11-pharmaceuticals-12-00156">11</xref>]. For example, overexpression of Ascl1 in mouse embryonic stem cells was shown to stimulate the production of neurons expressing a variety of neuronal markers, including pan-neural markers, such as neuronal class III β-tubulin (Tuj1) and microtubule associated protein 2 (MAP2); dopaminergic neuron markers, such as tyrosine hydroxylase and dopamine transporter; and motor neuron markers, such as islet 1 and 2 and the inhibitory neurotransmitter GABA [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>]. Overexpression of Neurog1/2 in human induced pluripotent stem cells was also shown to stimulate the production of neurons expressing MAP2, vesicular glutamate transporter 1, and choline acetyltransferase [<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>]. However, downstream neuronal genes regulated by these proneural transcription factors during the initial stages of neurogenesis have not been fully elucidated. We hypothesized that Ascl1 and Neurog1/2 might regulate novel common targets in this process. To test this, we performed a comparative transcriptome analysis using publicly available datasets to analyze genes expressed downstream of Ascl1 and Neurog1/2 in human and mouse embryonic stem cells [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>,<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>]. We then tested the function of one of the identified Ascl1 and Neurog1/2 common target genes, <italic>C3orf70</italic>, by examining the neural/neurobehavioral consequences of <italic>c3orf70</italic> gene knockout in zebrafish.</p>
</sec>
<sec id="sec2-pharmaceuticals-12-00156" sec-type="results">
<title>2. Results</title>
<sec id="sec2dot1-pharmaceuticals-12-00156">
<title>2.1. Comparative Transcriptome Analysis Reveals Common Target Genes of Neurog1/2 and Ascl1 in Stem Cells</title>
<p>To identify common targets of Neurog1/2 and Ascl1 in stem cells, we downloaded transcriptome datasets from human stem cells with and without overexpression of Neurog1/2 (GSE60548) [<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>] and from mouse stem cells with and without overexpression of Ascl1 (GSE43971) [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>] from the Gene Expression Omnibus [<xref ref-type="bibr" rid="B14-pharmaceuticals-12-00156">14</xref>]. Using these data, we identified differentially expressed genes (DEGs) regulated by Neurog1/2 or Ascl1 using a false discovery rate threshold of 10%. Venn diagrams of the numbers of DEGs in these datasets are shown in <xref ref-type="fig" rid="pharmaceuticals-12-00156-f001">Figure 1</xref>. One gene, <italic>C3orf70,</italic> was induced at days 1, 3, and 4 after induction of Neurog1/2 overexpression and at day 3, but not day 7, after induction of Ascl1 overexpression (<xref ref-type="table" rid="pharmaceuticals-12-00156-t001">Table 1</xref>). Fifteen additional genes were induced by Neurog1/2 at days 1, 3, and 4, and by Ascl1 at day 7, but none of them were induced by Ascl1 at day 3 (<xref ref-type="table" rid="pharmaceuticals-12-00156-t001">Table 1</xref>). No genes were commonly downregulated by both Neurog1/2 and Ascl1 on the same days (<xref ref-type="table" rid="pharmaceuticals-12-00156-t001">Table 1</xref>). </p>
<p>We next evaluated whether the 16 putative common target genes contained potential Neurog1/2 and Ascl1 binding sites by in silico analysis with Enrichr [<xref ref-type="bibr" rid="B15-pharmaceuticals-12-00156">15</xref>]. Indeed, 13 of the 16 genes contained potential binding sites for Ascl1, Neurog1, and/or Neurog2 in their promoters (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S1</xref>). Two other genes, cholinergic receptor nicotinic alpha 3 (<italic>Chrna3</italic>), and roundabout, axon guidance receptor homolog 2 (<italic>Robo2</italic>), lacked putative bindings sites for Ascl1, Neurog1, and/or Neurog2, but contained one for Neurod4, a bHLH proneural transcription factor that functions downstream of Neurog2 [<xref ref-type="bibr" rid="B16-pharmaceuticals-12-00156">16</xref>] (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S1</xref>). In addition, Enrichr-based functional analysis of 16 genes revealed significant enrichment of functions related to neuronal development (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S2</xref>), supporting a role for the putative Neurog1/2 and Ascl1 target genes in neuronal development.</p>
<p>Expression of <italic>C3orf70,</italic> one of the 16 genes identified as a common targets of Neurog1/2 and Ascl1, was previously shown to increase during Neurog2 and Ascl1-induced neuronal differentiation of P19 embryonic carcinoma cells [<xref ref-type="bibr" rid="B17-pharmaceuticals-12-00156">17</xref>]. To extend the Enrichr analysis, we used JASPAR, an open-access database of transcription factor-binding profiles [<xref ref-type="bibr" rid="B18-pharmaceuticals-12-00156">18</xref>], to investigate putative binding sites for Neurog2 and Ascl1 in the <italic>C3orf70</italic> sequence upstream of the transcription start site. This analysis confirmed the existence of binding sites in the human, mouse, and zebrafish <italic>C3orf70</italic> sequences (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Figure S1</xref>). Collectively, these in silico analyses support the results of the comparative transcriptome analysis and suggest that <italic>C3orf70</italic> is a conserved common target of Neurog2 and Ascl1 and has a potential role in neurogenesis.</p>
</sec>
<sec id="sec2dot2-pharmaceuticals-12-00156">
<title>2.2. Zebrafish Orthologs of C3orf70 Are Expressed in the Larval Midbrain and Hindbrain </title>
<p>The zebrafish genome is known to contain two orthologs of <italic>C3orf70</italic>; <italic>c3orf70a</italic> and <italic>c3orf70b</italic>, but to our knowledge, no studies have investigated their expression and function. We first amplified the <italic>c3orf70a</italic> and <italic>c3orf70b</italic> open reading frames using cDNA reverse-transcribed from zebrafish embryo RNA and compared the sequences with those in the NCBI Reference Sequence Database (NM_001126467 and NM_001089454). A single nucleotide difference was detected between the cDNAs and the reference sequences for both <italic>c3orf70a</italic> and <italic>c3orf70b</italic> (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Figures S2 and S3</xref>), but the inferred amino acid sequences and reference sequences were identical (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Figure S4</xref>). </p>
<p>We then examined the expression of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> in zebrafish using quantitative polymerase chain reaction (qPCR) and whole-mount in situ hybridization. qPCR analysis revealed increased expression of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> at 3 dpf compared with 1 dpf (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f002">Figure 2</xref>A), and whole-mount in situ hybridization revealed high expression of both <italic>c3orf70a</italic> and <italic>c3orf70b</italic> in the gut, myotomes, and brain, especially the midbrain and hindbrain, at 3 dpf (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f002">Figure 2</xref>B). Notably, the expression pattern of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> were very similar, suggesting that the two genes may have redundant functions in these tissues. </p>
</sec>
<sec id="sec2dot3-pharmaceuticals-12-00156">
<title>2.3. Generation of c3orf70-KO Zebrafish</title>
<p>To characterize the function of <italic>c3orf70</italic>, we generated <italic>c3orf70a</italic> and <italic>c3orf70b</italic> double knockout zebrafish (hereafter referred to as c3orf70-KO) using CRISPR/Cas9. We designed crRNAs to target these genes and injected them with tracRNA and Cas9 proteins into zebrafish embryos. After several rounds of genetic selection, we established c3orf70-KO zebrafish in which 10 and 20 bp were deleted in the <italic>c3orf70a</italic> and <italic>c3orf70b</italic> genes (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f003">Figure 3</xref>A,B), causing frame shifts that generated premature stop codons (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f003">Figure 3</xref>C). The c3orf70-KO zebrafish were viable and fertile.</p>
</sec>
<sec id="sec2dot4-pharmaceuticals-12-00156">
<title>2.4. Impaired Neuronal Marker Expression in c3orf70-KO Zebrafish</title>
<p>To analyze the functional role of <italic>c3orf70</italic> in neuronal development, we compared the expression of the neuronal markers neuronal differentiation 1 (<italic>neurod1</italic>), ELAV-like neuron-specific RNA binding protein 3 (<italic>elavl3</italic>), and enolase 2 (<italic>eno2</italic>) in c3orf70-WT and KO zebrafish. Neurod1 is a bHLH transcription factor commonly used as a proneural marker [<xref ref-type="bibr" rid="B19-pharmaceuticals-12-00156">19</xref>], Elavl3 regulates alternative splicing of several pre-mRNAs and has been used as a pan-neuronal marker [<xref ref-type="bibr" rid="B20-pharmaceuticals-12-00156">20</xref>], and Eno2 (enolase) is a glycolytic enzyme highly expressed in mature neurons [<xref ref-type="bibr" rid="B21-pharmaceuticals-12-00156">21</xref>]. Whole-mount in situ hybridization and qPCR analysis revealed that <italic>neurod1</italic> expression was not significantly different in c3orf70-WT and KO zebrafish (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f004">Figure 4</xref>A,C), whereas <italic>elavl3</italic> was present at significantly lower levels in c3orf70-KO compared with the WT zebrafish (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f004">Figure 4</xref>B,D). In vivo imaging of transgenic zebrafish in which the fluorescent protein cerulean was expressed in mature neurons under the control of the <italic>eno2</italic> promoter (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f004">Figure 4</xref>E) revealed a significant reduction in fluorescence in c3orf70-KO compared with WT zebrafish (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f004">Figure 4</xref>F). qPCR analysis of <italic>eno2</italic> revealed the same trend (data not shown). These results suggest that c3orf70 may regulate neuronal differentiation and maturation via <italic>elavl3</italic> and <italic>eno2</italic>. </p>
</sec>
<sec id="sec2dot5-pharmaceuticals-12-00156">
<title>2.5. WGCNA Identifies IRX3 as a Gene Coexpressed with C3orf70 During Neurogenesis</title>
<p>To analyze the potential molecular mechanisms by which <italic>c3orf70</italic> KO may impair neurogenesis in zebrafish, we performed weighted gene coexpression network analysis (WGCNA), which organizes transcriptomic data into networks based on gene coexpression to elucidate novel connections between genes [<xref ref-type="bibr" rid="B22-pharmaceuticals-12-00156">22</xref>,<xref ref-type="bibr" rid="B23-pharmaceuticals-12-00156">23</xref>]. Using WGCNA, we analyzed the transcriptome data of human stem cells with and without induction of Neurog1/2 overexpression (GSE60548) [<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>] and of mouse stem cells with and without induction of Ascl1 overexpression (GSE43971) [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>] and identified 1073 and 546 genes, respectively, coexpressed with <italic>C3orf70</italic> during neurogenesis. Of these, 31 genes, including the midbrain and hindbrain marker <italic>IRX3</italic> [<xref ref-type="bibr" rid="B24-pharmaceuticals-12-00156">24</xref>,<xref ref-type="bibr" rid="B25-pharmaceuticals-12-00156">25</xref>], were identified as commonly coexpressed with <italic>C3orf70</italic> after induction of both Neurog1/2 and Ascl1 (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f005">Figure 5</xref>A). qPCR analysis showed that expression of <italic>irx3b</italic>, a zebrafish ortholog of <italic>IRX3</italic>, was significantly reduced in c3orf70-KO zebrafish at 3 and 5 dpf (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f005">Figure 5</xref>B). These results suggest that impaired neurogenesis in c3orf70-KO zebrafish might be associated with disturbances in <italic>c3orf70</italic>-coexpressed genes such as <italic>irx3b</italic>.</p>
</sec>
<sec id="sec2dot6-pharmaceuticals-12-00156">
<title>2.6. Circadian Behavioral Responses Are Impaired in c3orf70-KO Zebrafish</title>
<p>Because the midbrain region, where zebrafish <italic>c3orf70</italic> orthologs are highly expressed, is one of the most important regions in controlling sleep–wake systems [<xref ref-type="bibr" rid="B26-pharmaceuticals-12-00156">26</xref>], we next compared the circadian behavior of c3orf70-WT and KO zebrafish by analyzing the distance moved and the time spent in movement during periods of light and dark (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f006">Figure 6</xref>A). During the dark period (21:00–07:00), the cumulative time spent at medium levels of mobility was significantly longer for c3orf70-KO compared with WT zebrafish (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f006">Figure 6</xref>D), whereas the total distance moved, the cumulative duration at high mobility, and cumulative duration in the center zone of the well (i.e., relative inactivity) were not significantly different between the WT and KO zebrafish (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f006">Figure 6</xref>B,C,E). During the light period, however (07:00–21:00), c3orf70-KO zebrafish displayed a significantly decreased total distance moved, cumulative duration at high mobility, and cumulative duration in the center zone compared with the WT zebrafish (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f006">Figure 6</xref>F,G,I). These results suggest that <italic>c3orf70</italic> deletion impaired the resting activity of zebrafish during the night and their explorative activity during the day.</p>
</sec>
<sec id="sec2dot7-pharmaceuticals-12-00156">
<title>2.7. Behavioral Responses to Alternating Light–Dark Cycles Is Impaired in c3orf70-KO Zebrafish</title>
<p>Previous studies have employed repeated cycling between relatively short periods of light and dark conditions (several minutes per condition) to examine the motor function and emotional behavior of zebrafish [<xref ref-type="bibr" rid="B27-pharmaceuticals-12-00156">27</xref>,<xref ref-type="bibr" rid="B28-pharmaceuticals-12-00156">28</xref>]. The midbrain contains several structures important in the regulation of motor function and emotion [<xref ref-type="bibr" rid="B29-pharmaceuticals-12-00156">29</xref>]. Therefore, we compared the behavior of c3orf70-WT and KO zebrafish in response to 3-min alternating intervals of light and dark. The total distance moved and cumulative duration at high mobility were both significantly decreased in c3orf70-KO zebrafish during both the light and dark periods (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f007">Figure 7</xref>B,C,F,G), whereas the cumulative duration in the center zone was significantly increased by c3orf70 KO only during the dark periods (<xref ref-type="fig" rid="pharmaceuticals-12-00156-f007">Figure 7</xref>I). These results suggest that attention and/or normal anxiety levels might be disrupted in c3orf70-KO zebrafish. </p>
</sec>
</sec>
<sec id="sec3-pharmaceuticals-12-00156" sec-type="discussion">
<title>3. Discussion</title>
<p>In this study, we identified <italic>C3orf70</italic> as a common target gene of Neurog1/2 and Ascl1 in human and mouse embryonic stem cells during neurogenesis. This finding is consistent with a previous report demonstrating that C3orf70 expression is increased during Neurog2- and Ascl1-initiated neuronal differentiation of the P19 mouse embryonic carcinoma cell line [<xref ref-type="bibr" rid="B17-pharmaceuticals-12-00156">17</xref>]. In addition, we identified putative binding sites for Neurog2 and Ascl1 in the <italic>C3orf70</italic> promoter of humans, mice, and zebrafish. We also investigated the expression and function of <italic>c3orf70</italic> in zebrafish and found that it was required for normal expression of the post-mitotic and mature neuron markers <italic>elavl3</italic> and <italic>eno2</italic> and the behaviors related to circadian rhythm and changes in light–dark conditions in zebrafish larvae. Collectively, these results suggest that C3orf70 is involved in neurogenesis and neurobehavior, and that impairments in C3orf70 expression and/or function may be linked to neurodevelopmental and neuropsychiatric disorders. </p>
<p>We were unable to identify any known functional motifs in the amino acid sequence of C3orf70 that might point to its potential mechanism of action in neurogenesis and neurobehavior. Therefore, we sought to identify genes coexpressed with <italic>C3orf70</italic> during neurogenesis. Of the 31 genes identified, two, <italic>IRX3</italic> and <italic>SOX5</italic>, were of particular interest [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>,<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>]. <italic>IRX3</italic> is highly expressed in the midbrain and hindbrain of vertebrates, including zebrafish (<italic>irx3</italic>), and is involved in neurogenesis [<xref ref-type="bibr" rid="B24-pharmaceuticals-12-00156">24</xref>,<xref ref-type="bibr" rid="B25-pharmaceuticals-12-00156">25</xref>,<xref ref-type="bibr" rid="B30-pharmaceuticals-12-00156">30</xref>]. The midbrain is involved in regulation of circadian behavior and behavioral responses related to motor function and emotion [<xref ref-type="bibr" rid="B27-pharmaceuticals-12-00156">27</xref>,<xref ref-type="bibr" rid="B28-pharmaceuticals-12-00156">28</xref>] [<xref ref-type="bibr" rid="B26-pharmaceuticals-12-00156">26</xref>,<xref ref-type="bibr" rid="B29-pharmaceuticals-12-00156">29</xref>], which we confirmed were disrupted in c3orf70-KO zebrafish. These findings suggest that C3orf70 may regulate neurogenesis and neurobehavioral development via interactions with coexpressed genes such as <italic>IRX3</italic>. It is also noteworthy that both <italic>C3orf70</italic> and <italic>IRX3</italic> are genetically associated with obesity [<xref ref-type="bibr" rid="B31-pharmaceuticals-12-00156">31</xref>,<xref ref-type="bibr" rid="B32-pharmaceuticals-12-00156">32</xref>]. <italic>SOX5</italic> is associated with neuronal development, intellectual disability, and autism [<xref ref-type="bibr" rid="B33-pharmaceuticals-12-00156">33</xref>,<xref ref-type="bibr" rid="B34-pharmaceuticals-12-00156">34</xref>,<xref ref-type="bibr" rid="B35-pharmaceuticals-12-00156">35</xref>]. Interestingly, genetic analyses have demonstrated that C3orf70 is associated with educational attainment [<xref ref-type="bibr" rid="B36-pharmaceuticals-12-00156">36</xref>], major depressive disorder [<xref ref-type="bibr" rid="B37-pharmaceuticals-12-00156">37</xref>], and insomnia [<xref ref-type="bibr" rid="B38-pharmaceuticals-12-00156">38</xref>]. Although we could not detect a significant difference in the expression of <italic>sox5</italic> in c3orf70-KO and WT zebrafish using qPCR (data not shown), SOX5, similar to C3orf70, is highly expressed in the midbrain [<xref ref-type="bibr" rid="B39-pharmaceuticals-12-00156">39</xref>], suggesting a possible link in their function. Additional analyses, such as in situ hybridization, may shed light on the differential expression of <italic>sox5</italic> in WT and c3orf70-KO zebrafish. Moreover, further studies will be required to fully elucidate the mechanisms by which C3orf70 regulates IRX3 and SOX5 expression as well as their involvement in neurogenesis and neurobehavior. In this regard, it will be important to analyze zebrafish with single- and double-KO of <italic>c3orf70a/c3orf70b</italic> over many generations to clarify the function of the two genes and to exclude possible off-target effects of CRISPR/Cas9-induced mutations. Rescue experiments involving injection of mRNA encoding c3orf70a and/or c3orf70b will also be required. </p>
<p>In this study, we used zebrafish as a model organism in which to analyze the function of <italic>c3orf70</italic>. Zebrafish have been successfully used to characterize the function of numerous genes in vivo [<xref ref-type="bibr" rid="B40-pharmaceuticals-12-00156">40</xref>,<xref ref-type="bibr" rid="B41-pharmaceuticals-12-00156">41</xref>] and to find novel therapeutics for various diseases [<xref ref-type="bibr" rid="B42-pharmaceuticals-12-00156">42</xref>,<xref ref-type="bibr" rid="B43-pharmaceuticals-12-00156">43</xref>]. Although zebrafish and mammals display several key developmental differences, such as ex utero development and the eversion of telencephalic hemispheres in zebrafish, comparative neurogenetic and neuroanatomical analyses have revealed a high degree of conservation in neurogenesis between zebrafish and mammals [<xref ref-type="bibr" rid="B28-pharmaceuticals-12-00156">28</xref>,<xref ref-type="bibr" rid="B44-pharmaceuticals-12-00156">44</xref>,<xref ref-type="bibr" rid="B45-pharmaceuticals-12-00156">45</xref>]. Moreover, zebrafish express orthologs of many molecules that are therapeutic targets in humans [<xref ref-type="bibr" rid="B46-pharmaceuticals-12-00156">46</xref>]. Although some studies have shown differences in pharmacodynamics between zebrafish and humans [<xref ref-type="bibr" rid="B47-pharmaceuticals-12-00156">47</xref>,<xref ref-type="bibr" rid="B48-pharmaceuticals-12-00156">48</xref>], many other studies have demonstrated the utility of zebrafish to identify novel drugs and to investigate the safety of drugs in preclinical and clinical development [<xref ref-type="bibr" rid="B28-pharmaceuticals-12-00156">28</xref>,<xref ref-type="bibr" rid="B43-pharmaceuticals-12-00156">43</xref>,<xref ref-type="bibr" rid="B49-pharmaceuticals-12-00156">49</xref>,<xref ref-type="bibr" rid="B50-pharmaceuticals-12-00156">50</xref>,<xref ref-type="bibr" rid="B51-pharmaceuticals-12-00156">51</xref>]. The results of the present study suggest that c30rf70-KO zebrafish may be useful for understanding the pathophysiology of neurodevelopmental and neuropsychiatric disorders related to C3orf70 function, and to identify novel drugs to treat these disorders. It should be noted, however, that we were not able to examine the function of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> separately in this study, and further experiments will be required to clarify their individual roles.</p>
<p>In conclusion, we performed a comparative transcriptomic analysis of neurogenesis of human and mouse stem cells and identified <italic>C3orf70</italic> as a novel common target of Neurog1/2 and Ascl1. Using zebrafish, we demonstrated that <italic>c3orf70</italic> is involved in neurogenesis and neurobehavior. These results suggest that impairments in C3orf70 might be related to human neurodevelopmental and neuropsychiatric disorders, and they provide a strong rationale for further characterization of C3orf70 as a potential therapeutic target. </p>
</sec>
<sec id="sec4-pharmaceuticals-12-00156">
<title>4. Materials and Methods</title>
<sec id="sec4dot1-pharmaceuticals-12-00156">
<title>4.1. Ethics Statement</title>
<p>Mie University Institutional Animal Care and Use Committee guidelines state that no approval is required for experiments using zebrafish. However, all animal experiments described in this manuscript conform to the ethical guidelines established by the Institutional Animal Care and Use Committee at Mie University.</p>
</sec>
<sec id="sec4dot2-pharmaceuticals-12-00156">
<title>4.2. Comparative Transcriptome Analysis</title>
<p>To compare DEGs caused by the activation of Neurog1/2 or Ascl1 in human or mouse stem cells, respectively, we used two transcriptome datasets deposited in the Gene Expression Omnibus (GEO) [<xref ref-type="bibr" rid="B52-pharmaceuticals-12-00156">52</xref>]. The normalized transcriptome analysis data of human (GSE60548) [<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>] and mouse stem cells (GSE43971) [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>] were downloaded from GEO and subjected to “RankProd” [<xref ref-type="bibr" rid="B53-pharmaceuticals-12-00156">53</xref>] in Bioconductor [<xref ref-type="bibr" rid="B54-pharmaceuticals-12-00156">54</xref>] to identify the DEGs using a false discovery rate threshold of 10%. The gene symbols of the DEGs in mouse stem cells were converted to the human orthologs using the Life Science Knowledge Bank (World Fusion, Tokyo, Japan). </p>
</sec>
<sec id="sec4dot3-pharmaceuticals-12-00156">
<title>4.3. Bioinformatic Analysis of Common DEGs</title>
<p>We used Enrichr [<xref ref-type="bibr" rid="B15-pharmaceuticals-12-00156">15</xref>] to identify transcription factors that potentially regulate the identified DEGs and to examine the putative biological functions enriched for each common DEG. Briefly, a list of common DEGs (<xref ref-type="table" rid="pharmaceuticals-12-00156-t001">Table 1</xref>) was subjected to Enrichr analysis, and factors/processes returned in the “Enrichr Submissions TF-Gene Cooccurrence” (adjusted <italic>p</italic> &lt; 1 × 10<sup>−6</sup>) and “GO Biological Process 2018” (adjusted <italic>p</italic> &lt; 0.05) were identified as transcription factors potentially regulating the common DEGs (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S1</xref>) and biological functions enriched in the common DEGs (<xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S2</xref>), respectively. JASPAR [<xref ref-type="bibr" rid="B18-pharmaceuticals-12-00156">18</xref>] was used to identify the putative binding sites for Neurog2 and Ascl1 transcription factors in a 3000 bp sequence upstream of the transcription start site in human, mouse, and zebrafish <italic>C3orf70</italic>. </p>
</sec>
<sec id="sec4dot4-pharmaceuticals-12-00156">
<title>4.4. Zebrafish Husbandry</title>
<p>We used the Tg (<italic>eno2</italic>: Cerulean) zebrafish line [<xref ref-type="bibr" rid="B55-pharmaceuticals-12-00156">55</xref>] to derive the strains generated here. Zebrafish were maintained as described previously [<xref ref-type="bibr" rid="B50-pharmaceuticals-12-00156">50</xref>]. Briefly, zebrafish were raised at 28.5 ± 0.5 °C with a 14 h/10 h light/dark cycle. Embryos were obtained via natural mating and cultured in 0.3× Danieau’s solution (19.3 mM NaCl, 0.23 mM KCl, 0.13 mM MgSO<sub>4</sub>, 0.2 mM Ca(NO<sub>3</sub>)<sub>2</sub>, 1.7 mM HEPES, pH 7.2). </p>
</sec>
<sec id="sec4dot5-pharmaceuticals-12-00156">
<title>4.5. Generation of c3orf70-KO Zebrafish </title>
<p>C3orf70-KO zebrafish were generated according to methods described previously [<xref ref-type="bibr" rid="B56-pharmaceuticals-12-00156">56</xref>,<xref ref-type="bibr" rid="B57-pharmaceuticals-12-00156">57</xref>], with some modifications. Briefly, CRISPR RNA (crRNA) targeting the <italic>c3orf70a</italic> (<italic>si:dkey-22o12.2</italic>) or <italic>c3orf70b</italic> (<italic>zgc:162707</italic>) genes and trans-activating crRNA (tracrRNA) [<xref ref-type="bibr" rid="B58-pharmaceuticals-12-00156">58</xref>] were obtained from FASMAC (Kanagawa, Japan) (sequences shown in <xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S3</xref>). Recombinant Cas9 protein was obtained from Toolgen (Seoul, Korea). crRNA, tracrRNA, and Cas9 protein were dissolved in sterilized water (1000 ng/µL) and stored at −80 °C until required. For microinjection, crRNAs, tracrRNA, Cas9 protein, and a lissamine-labeled control morpholino with no known target gene (Gene Tools, Philomath, OR, USA) were mixed in Diethylpyrocarbonate ()-treated water to final concentrations of 200 ng/µL (100 ng/µL each), 100 ng/µL, 400 ng/µL, and 50 nM, respectively. The solution was injected into 1-cell-stage zebrafish embryos derived from the Tg (eno2: cerulean) line. At 4 months post-fertilization, genomic DNA was extracted from the fins of F0 zebrafish and used to detect CRISPR/Cas9-induced mutations according to previous reports [<xref ref-type="bibr" rid="B59-pharmaceuticals-12-00156">59</xref>,<xref ref-type="bibr" rid="B60-pharmaceuticals-12-00156">60</xref>] with some modifications as follows. A short fragment of the <italic>c3orf70a</italic> or <italic>c3orf70b</italic> gene encompassing the target sites was amplified from genomic DNA using the primers shown in <xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S3</xref>. Three-step PCR was carried out using 40 cycles of 94 °C for 30 s, 60 °C for 30 s, and 68 °C for 30 s. The PCR products were electrophoresed in 10% polyacrylamide gels as described previously [<xref ref-type="bibr" rid="B59-pharmaceuticals-12-00156">59</xref>,<xref ref-type="bibr" rid="B60-pharmaceuticals-12-00156">60</xref>] and F0 fish in which the CRISPR/Cas9-induced mutation was present were crossed with the Tg(<italic>eno2</italic>: Cerulean) zebrafish line to obtain F1 progeny (<italic>c3orf70a+/-</italic>:<italic>c3orf70b+/+</italic> or <italic>c3orf70a+/+</italic>:<italic>c3orf70b+/-</italic>). The F1 generation was reared and screened for the presence of the mutation by PCR, as described above. F1 female and male hetero-KO zebrafish harboring the same mutations in the <italic>c3orf70a</italic> or <italic>c3orf70b</italic> gene were crossed to obtain F2 progeny (<italic>c3orf70a-/-</italic>:<italic>c3orf70b+/</italic>+, <italic>c3orf70a+/+</italic>:<italic>c3orf70b-/</italic>-, and <italic>c3orf70a+/-</italic>:<italic>c3orf70b+/</italic>-). The PCR product corresponding to the homo-KO of <italic>c3orf70a</italic> or <italic>c3orf70b</italic> was subjected to sequence analysis using ExoSAP-IT Express PCR Cleanup Reagents (Thermo Fisher, MA, USA) according to the manufacturer’s protocol. F2 fish (<italic>c3orf70a+/-</italic>:<italic>c3orf70b+/</italic>-) with a homozygous genotype (validated to have the frame shift mutation, as shown in <xref ref-type="fig" rid="pharmaceuticals-12-00156-f002">Figure 2</xref>) were used to generate F3 progeny (<italic>c3orf70a-/-</italic>:<italic>c3orf70b-/-</italic>). The F3 generation was reared and crossed to obtain F4 progeny. The F4 generation was characterized in this study. The PCR product corresponding to the WT or homo-KO of <italic>c3orf70a</italic> or <italic>c3orf70b</italic> cDNA was also subjected to sequence analysis as shown above.</p>
</sec>
<sec id="sec4dot6-pharmaceuticals-12-00156">
<title>4.6. Whole-Mount In Situ Hybridization of Neuronal Markers</title>
<p>Whole-mount in situ hybridization was performed as described previously [<xref ref-type="bibr" rid="B61-pharmaceuticals-12-00156">61</xref>,<xref ref-type="bibr" rid="B62-pharmaceuticals-12-00156">62</xref>] with some modifications. Briefly, cDNA fragments of <italic>c3orf70a</italic>, <italic>c3orf70b, neurod1,</italic> and <italic>elavl3</italic> were amplified using the primers shown in <xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S3</xref>. The PCR products were cloned into the pGEM-T vector (Promega, WI, USA) and sequence analysis was performed to verify insertion in the correct orientation. Antisense probes were synthesized using the DIG RNA Labeling Kit (Sigma-Aldrich, MO, USA). c3orf70-KO or WT Tg (eno2: cerulean) zebrafish were fixed at 2 dpf (<italic>neurod1</italic> and <italic>elavl3</italic>) and 3 dpf (<italic>c3orf70a</italic> and <italic>c3orf70b</italic>) for whole-mount in situ hybridization.</p>
</sec>
<sec id="sec4dot7-pharmaceuticals-12-00156">
<title>4.7. qPCR Analysis</title>
<p>qPCR analysis was performed as described previously [<xref ref-type="bibr" rid="B42-pharmaceuticals-12-00156">42</xref>,<xref ref-type="bibr" rid="B60-pharmaceuticals-12-00156">60</xref>] with some modifications. Briefly, total RNA was extracted from Tg (eno2: cerulean) zebrafish using a Nucleospin RNA XS kit (Takara, Kyoto, Japan) according to the manufacturer’s protocol. cDNA was generated using a ReverTra Ace qPCR RT Kit (Toyobo). qPCR was performed using an ABI Prism 7300 PCR system (Life Technologies, Carlsbad, CA, USA) with THUNDERBIRD SYBR qPCR Mix (Toyobo). The thermal cycling conditions were: 95 °C for 1 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 15 s, and 72 °C for 45 s. mRNA expression of <italic>neurod1, elavl3, eno2</italic> and <italic>irx3b</italic> was normalized to that of β-actin (<italic>actb</italic>) to correct for variability in the initial template concentration and reverse transcription efficiency. The primer sequences are shown in <xref ref-type="app" rid="app1-pharmaceuticals-12-00156">Supplemental Table S3</xref>.</p>
</sec>
<sec id="sec4dot8-pharmaceuticals-12-00156">
<title>4.8. Weighted Gene Coexpression Network Analysis</title>
<p>The coefficient of variation (CV) of the normalized probe intensity for each gene in the GSE60548 [<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>] and GSE43971 [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>] transcriptome datasets was calculated, and genes were sorted in descending order by CV. The top 3000 genes were subjected to WGCNA [<xref ref-type="bibr" rid="B63-pharmaceuticals-12-00156">63</xref>] in Bioconductor [<xref ref-type="bibr" rid="B54-pharmaceuticals-12-00156">54</xref>]. <italic>C3orf70</italic> was included in the top 3000 gene lists from both transcriptome datasets. Seven and 13 modules were classified based on coexpression between the top 3000 genes of GSE60548 and GSE43971, respectively. <italic>C3orf70</italic> was included in the turquoise modules in both datasets. Genes coexpressed with <italic>C3orf70</italic> in each turquoise module were selected using thresholds of 0.1. The relationships were analyzed in Cytoscape [<xref ref-type="bibr" rid="B64-pharmaceuticals-12-00156">64</xref>] to identify and draw the common network between <italic>C3orf70</italic> and the coexpressed genes in both datasets.</p>
</sec>
<sec id="sec4dot9-pharmaceuticals-12-00156">
<title>4.9. In Vivo Imaging of Tg (eno2: Cerulean) Zebrafish</title>
<p>At 5 dpf, c3orf70-KO or WT Tg (eno2: cerulean) zebrafish were anesthetized with 2-phenoxyethanol and placed in a 96-well imaging plate (ZF plate, Hashimoto Electric Industry, Mie, Japan). In vivo imaging and quantitative analysis of the cerulean fluorescence signal was performed using ImageXpress Micro with customized programs (Molecular Device, Sunnyvale, CA, USA). Brain and spinal cord regions expressing <italic>eno2</italic> promoter-driven cerulean fluorescence above a defined threshold were automatically detected and the areas were quantified.</p>
</sec>
<sec id="sec4dot10-pharmaceuticals-12-00156">
<title>4.10. Behavioral Analysis</title>
<p>At 7 dpf, zebrafish were placed individually into the wells of a 48-well plate (10 mm radius, 800 µL of 0.3× Danieau’s solution) at 20:00 (n = 20–24 for each group). The 48-well plate was placed in an incubator at 28.5 °C with constant light (255 lx) between 20:00–21:00 and then placed in a DanioVision system (Noldus, Wageningen, The Netherlands), which analyzes circadian behavior. The 48-well plate in DanioVision was kept at 28.5 °C in the dark between 21:00 and 07:00 and illuminated from below with white light (255 lx) between 07:00 and 21:00. After circadian behavior analysis, behavioral responses to light–dark changes were analyzed using 10 cycles of alternating light and dark, consisting of illumination with white light (255 lx) for 3 min followed by no light for 3 min. Zebrafish behavior was monitored in each well by DanioVision at a resolution of 1024 × 768 pixels and 25 frames per second. Two independent experiments were performed. All recorded video images were subjected to EthoVision XT11 (Noldus) to measure total distance moved, cumulative time spent at high or medium mobility, and cumulative time spent in the center zone (circle of 2 mm radius) of the well. Mobility was calculated by comparing every pixel in the current and previous images. If all pixels were identical, zero mobility was recorded. If all pixels were different, 100% mobility was recorded. In this study, we defined medium and high mobility as 35–65% and 65–95% difference in pixels, respectively.</p>
</sec>
<sec id="sec4dot11-pharmaceuticals-12-00156">
<title>4.11. Statistical analysis</title>
<p>Statistical analysis was performed using Prism 7 (GraphPad, La Jolla, CA, USA). Mann–Whitney tests were performed to assess differences between neuronal marker expression, and two-way ANOVA was performed to assess zebrafish behavior and <italic>irx3b</italic> expression. Data are presented as the mean ±SEM of the indicated number of zebrafish.</p>
</sec>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>We are grateful to Mitsunari Yamaguchi (Molecular Device) for creating the programs used in ImageXpress Micro, and Shinji Umezawa (Sophia Scientific) for advice on the use of DanioVision. We would like to thank Rie Ikeyama and Junko Koiwa for secretarial and experimental assistance, respectively. We also thank Amy Birch, PhD, and Anne M. O’Rourke, PhD, from Edanz Group (<uri xlink:href="www.edanzediting.com/ac">www.edanzediting.com/ac</uri>) for editing the drafts of this manuscript.</p>
</ack>
<app-group>
<app id="app1-pharmaceuticals-12-00156">
<title>Supplementary Materials</title>
<p>The following are available online at <uri xlink:href="https://www.mdpi.com/1424-8247/12/4/156/s1">https://www.mdpi.com/1424-8247/12/4/156/s1</uri>, Figure S1: Comparison of the putative binding sites for Neurog2 and Ascl1 in the promoter sequence of C3orf70. Figure S2: Comparison of the nucleotide sequences of c3orf70a open reading frame determined in this study and human sequence NM_001126467 in the NCBI Reference Sequence Database. Figure S3: Comparison of the nucleotide sequences of c3orf70b open reading frame determined in this study and NM_001089454 in the NCBI Reference Sequence Database. Figure S4: Comparison of the inferred amino acid sequences of c3orf70a and c3orf70b open reading frames obtained in this study and NCBI reference sequences NM_001126467 and NM_001089454. Table S1: Transcription factors enriched in the promoters of differentially expressed genes regulated by Neurog1/2 and Ascl1. Table S2: Biological process enriched in the differentially expressed genes regulated by Neurog1/2 and Ascl1. Table S3: crRNA, tracrRNA, and PCR primer nucleotide sequences used for this study.</p>
<supplementary-material content-type="local-data" id="pharmaceuticals-12-00156-s001">
<media xlink:href="pharmaceuticals-12-00156-s001.pdf">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</app>
</app-group>
<notes>
<title>Author Contributions</title>
<p>Conceptualization, Y.N.; Methodology, Y.A. (Yoshifumi Ashikawa) and Y.N.; Validation, Y.A. (Yoshifumi Ashikawa), T.S., K.M., Y.A. (Yuka Adachi) and Y.N.; Formal Analysis, Y.A. (Yoshifumi Ashikawa). T.S., K.M. and Y.N.; Investigation, Y.A. (Yoshifumi Ashikawa). T.S., K.M. and Y.N.; Resources, T.M., Y.B. and T.T.; Data Curation, Y.A. (Yoshifumi Ashikawa). T.S., K.M. and Y.N.; Writing—Original Draft Preparation, Y.N.; Visualization, Y.A. (Yoshifumi Ashikawa) and Y.N.; Supervision, Y.N.; Project Administration, Y.N.; Funding Acquisition, T.S. and Y.N.</p>
</notes>
<notes>
<title>Funding</title>
<p>This work was supported in part by the Japan Society for the Promotion of Science KAKENHI (16K08547, 18K06890, 19K07318) and Takeda Science Foundation.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-pharmaceuticals-12-00156">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marchetto</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Belinson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Freitas</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Vadodaria</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Beltrao-Braga</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Trujillo</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Mendes</surname>
<given-names>A.P.D.</given-names>
</name>
<name>
<surname>Padmanabhan</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Altered proliferation and networks in neural cells derived from idiopathic autistic individuals</article-title>
<source/>Mol. Psychiatry
          <year>2017</year>
<volume>22</volume>
<fpage>820</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="doi">10.1038/mp.2016.95</pub-id>
<pub-id pub-id-type="pmid">27378147</pub-id>
</element-citation>
</ref>
<ref id="B2-pharmaceuticals-12-00156">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sacco</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Cacci</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Novarino</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Neural stem cells in neuropsychiatric disorders</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>2018</year>
<volume>48</volume>
<fpage>131</fpage>
<lpage>138</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2017.12.005</pub-id>
<pub-id pub-id-type="pmid">29287246</pub-id>
</element-citation>
</ref>
<ref id="B3-pharmaceuticals-12-00156">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adhya</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Swarup</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shum</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nowosiad</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Jozwik</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Skuse</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Flinter</surname>
<given-names>F.A.</given-names>
</name>
<name>
<surname>McAlonan</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Atypical neurogenesis and excitatory-inhibitory progenitor generation in induced pluripotent stem cell (iPSC) from autistic individuals</article-title>
<source/>bioRxiv
          <year>2019</year>
<pub-id pub-id-type="doi">10.1101/349415</pub-id>
</element-citation>
</ref>
<ref id="B4-pharmaceuticals-12-00156">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakano-Kobayashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Awaya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kii</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sumida</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okuno</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yoshida</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sumida</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hosoya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2017</year>
<volume>114</volume>
<fpage>10268</fpage>
<lpage>10273</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1704143114</pub-id>
<pub-id pub-id-type="pmid">28874550</pub-id>
</element-citation>
</ref>
<ref id="B5-pharmaceuticals-12-00156">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bardoni</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Capovilla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lalli</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Modeling Fragile X syndrome in neurogenesis: An unexpected phenotype and a novel tool for future therapies</article-title>
<source/>Neurogenesis
          <year>2017</year>
<volume>4</volume>
<fpage>e1270384</fpage>
<pub-id pub-id-type="doi">10.1080/23262133.2016.1270384</pub-id>
<pub-id pub-id-type="pmid">28203608</pub-id>
</element-citation>
</ref>
<ref id="B6-pharmaceuticals-12-00156">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chaudhury</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Neuronal correlates of depression</article-title>
<source/>Cell. Mol. Life Sci.
          <year>2015</year>
<volume>72</volume>
<fpage>4825</fpage>
<lpage>4848</lpage>
<pub-id pub-id-type="doi">10.1007/s00018-015-2044-6</pub-id>
<pub-id pub-id-type="pmid">26542802</pub-id>
</element-citation>
</ref>
<ref id="B7-pharmaceuticals-12-00156">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baptista</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>J.P.</given-names>
</name>
</person-group>
<article-title>Adult Hippocampal Neurogenesis: Regulation and Possible Functional and Clinical Correlates</article-title>
<source/>Front. Neuroanat.
          <year>2018</year>
<volume>12</volume>
<fpage>44</fpage>
<pub-id pub-id-type="doi">10.3389/fnana.2018.00044</pub-id>
<pub-id pub-id-type="pmid">29922131</pub-id>
</element-citation>
</ref>
<ref id="B8-pharmaceuticals-12-00156">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inta</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Lang</surname>
<given-names>U.E.</given-names>
</name>
<name>
<surname>Borgwardt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gass</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning</article-title>
<source/>Schizophr. Bull.
          <year>2017</year>
<volume>43</volume>
<fpage>493</fpage>
<lpage>496</lpage>
<pub-id pub-id-type="doi">10.1093/schbul/sbw088</pub-id>
<pub-id pub-id-type="pmid">27352782</pub-id>
</element-citation>
</ref>
<ref id="B9-pharmaceuticals-12-00156">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hartenstein</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stollewerk</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The evolution of early neurogenesis</article-title>
<source/>Dev. Cell
          <year>2015</year>
<volume>32</volume>
<fpage>390</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="doi">10.1016/j.devcel.2015.02.004</pub-id>
<pub-id pub-id-type="pmid">25710527</pub-id>
</element-citation>
</ref>
<ref id="B10-pharmaceuticals-12-00156">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilkinson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dennis</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schuurmans</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Proneural genes in neocortical development</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>253</volume>
<fpage>256</fpage>
<lpage>273</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2013.08.029</pub-id>
<pub-id pub-id-type="pmid">23999125</pub-id>
</element-citation>
</ref>
<ref id="B11-pharmaceuticals-12-00156">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guillemot</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Beyond proneural: Emerging functions and regulations of proneural proteins</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>2017</year>
<volume>42</volume>
<fpage>93</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1016/j.conb.2016.11.011</pub-id>
<pub-id pub-id-type="pmid">28025176</pub-id>
</element-citation>
</ref>
<ref id="B12-pharmaceuticals-12-00156">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamizu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Piao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sharov</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Zsiros</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schlessinger</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>M.S.</given-names>
</name>
</person-group>
<article-title>Identification of transcription factors for lineage-specific ESC differentiation</article-title>
<source/>Stem Cell Rep.
          <year>2013</year>
<volume>1</volume>
<fpage>545</fpage>
<lpage>559</lpage>
<pub-id pub-id-type="doi">10.1016/j.stemcr.2013.10.006</pub-id>
<pub-id pub-id-type="pmid">24371809</pub-id>
</element-citation>
</ref>
<ref id="B13-pharmaceuticals-12-00156">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Busskamp</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>Guye</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>A.H.</given-names>
</name>
<name>
<surname>Shipman</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Byrne</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Sanjana</surname>
<given-names>N.E.</given-names>
</name>
<name>
<surname>Murn</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rapid neurogenesis through transcriptional activation in human stem cells</article-title>
<source/>Mol. Syst. Biol.
          <year>2014</year>
<volume>10</volume>
<fpage>760</fpage>
<pub-id pub-id-type="doi">10.15252/msb.20145508</pub-id>
<pub-id pub-id-type="pmid">25403753</pub-id>
</element-citation>
</ref>
<ref id="B14-pharmaceuticals-12-00156">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Troup</surname>
<given-names>D.B.</given-names>
</name>
<name>
<surname>Wilhite</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Ledoux</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rudnev</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.F.</given-names>
</name>
<name>
<surname>Soboleva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tomashevsky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>K.A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NCBI GEO: Archive for high-throughput functional genomic data</article-title>
<source/>Nucleic Acids Res.
          <year>2009</year>
<volume>37</volume>
<fpage>D885</fpage>
<lpage>D890</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkn764</pub-id>
<pub-id pub-id-type="pmid">18940857</pub-id>
</element-citation>
</ref>
<ref id="B15-pharmaceuticals-12-00156">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuleshov</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Rouillard</surname>
<given-names>A.D.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Koplev</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jenkins</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Jagodnik</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Lachmann</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enrichr: A comprehensive gene set enrichment analysis web server 2016 update</article-title>
<source/>Nucleic Acids Res.
          <year>2016</year>
<volume>44</volume>
<fpage>W90</fpage>
<lpage>W97</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkw377</pub-id>
<pub-id pub-id-type="pmid">27141961</pub-id>
</element-citation>
</ref>
<ref id="B16-pharmaceuticals-12-00156">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hardwick</surname>
<given-names>L.J.</given-names>
</name>
<name>
<surname>Philpott</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Multi-site phosphorylation regulates NeuroD4 activity during primary neurogenesis: A conserved mechanism amongst proneural proteins</article-title>
<source/>Neural Dev.
          <year>2015</year>
<volume>10</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.1186/s13064-015-0044-8</pub-id>
<pub-id pub-id-type="pmid">26084567</pub-id>
</element-citation>
</ref>
<ref id="B17-pharmaceuticals-12-00156">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Redmond</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Kubish</surname>
<given-names>G.M.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Uhler</surname>
<given-names>M.D.</given-names>
</name>
</person-group>
<article-title>Transcriptional regulatory events initiated by Ascl1 and Neurog2 during neuronal differentiation of P19 embryonic carcinoma cells</article-title>
<source/>J. Mol. Neurosci.
          <year>2015</year>
<volume>55</volume>
<fpage>684</fpage>
<lpage>705</lpage>
<pub-id pub-id-type="doi">10.1007/s12031-014-0408-2</pub-id>
<pub-id pub-id-type="pmid">25189318</pub-id>
</element-citation>
</ref>
<ref id="B18-pharmaceuticals-12-00156">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fornes</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Stigliani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gheorghe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Castro-Mondragon</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>van der Lee</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bessy</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cheneby</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>S.R.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>JASPAR 2018: Update of the open-access database of transcription factor binding profiles and its web framework</article-title>
<source/>Nucleic Acids Res.
          <year>2018</year>
<volume>46</volume>
<fpage>D260</fpage>
<lpage>D266</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkx1126</pub-id>
<pub-id pub-id-type="pmid">29140473</pub-id>
</element-citation>
</ref>
<ref id="B19-pharmaceuticals-12-00156">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>The role of BETA2/NeuroD1 in the development of the nervous system</article-title>
<source/>Mol. Neurobiol.
          <year>2004</year>
<volume>30</volume>
<fpage>35</fpage>
<lpage>47</lpage>
<pub-id pub-id-type="doi">10.1385/MN:30:1:035</pub-id>
<pub-id pub-id-type="pmid">15247487</pub-id>
</element-citation>
</ref>
<ref id="B20-pharmaceuticals-12-00156">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ince-Dunn</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Okano</surname>
<given-names>H.J.</given-names>
</name>
<name>
<surname>Jensen</surname>
<given-names>K.B.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>W.Y.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ule</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mele</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fak</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuronal Elav-like (Hu) proteins regulate RNA splicing and abundance to control glutamate levels and neuronal excitability</article-title>
<source/>Neuron
          <year>2012</year>
<volume>75</volume>
<fpage>1067</fpage>
<lpage>1080</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2012.07.009</pub-id>
<pub-id pub-id-type="pmid">22998874</pub-id>
</element-citation>
</ref>
<ref id="B21-pharmaceuticals-12-00156">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isgro</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Bottoni</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Scatena</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects</article-title>
<source/>Adv. Exp. Med. Biol.
          <year>2015</year>
<volume>867</volume>
<fpage>125</fpage>
<lpage>143</lpage>
<pub-id pub-id-type="pmid">26530364</pub-id>
</element-citation>
</ref>
<ref id="B22-pharmaceuticals-12-00156">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oldham</surname>
<given-names>M.C.</given-names>
</name>
<name>
<surname>Konopka</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Iwamoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Langfelder</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Geschwind</surname>
<given-names>D.H.</given-names>
</name>
</person-group>
<article-title>Functional organization of the transcriptome in human brain</article-title>
<source/>Nat. Neurosci.
          <year>2008</year>
<volume>11</volume>
<fpage>1271</fpage>
<lpage>1282</lpage>
<pub-id pub-id-type="doi">10.1038/nn.2207</pub-id>
<pub-id pub-id-type="pmid">18849986</pub-id>
</element-citation>
</ref>
<ref id="B23-pharmaceuticals-12-00156">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.Z.</given-names>
</name>
</person-group>
<article-title>Understanding Molecular Mechanisms of the Brain Through Transcriptomics</article-title>
<source/>Front. Physiol.
          <year>2019</year>
<volume>10</volume>
<fpage>214</fpage>
<pub-id pub-id-type="doi">10.3389/fphys.2019.00214</pub-id>
<pub-id pub-id-type="pmid">30930788</pub-id>
</element-citation>
</ref>
<ref id="B24-pharmaceuticals-12-00156">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bosse</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zulch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>M.B.</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gomez-Skarmeta</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Modolell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gruss</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Identification of the vertebrate Iroquois homeobox gene family with overlapping expression during early development of the nervous system</article-title>
<source/>Mech. Dev.
          <year>1997</year>
<volume>69</volume>
<fpage>169</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1016/S0925-4773(97)00165-2</pub-id>
<pub-id pub-id-type="pmid">9486539</pub-id>
</element-citation>
</ref>
<ref id="B25-pharmaceuticals-12-00156">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robertshaw</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lumsden</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kiecker</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Irx3 and Pax6 establish differential competence for Shh-mediated induction of GABAergic and glutamatergic neurons of the thalamus</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2013</year>
<volume>110</volume>
<fpage>E3919</fpage>
<lpage>E3926</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1304311110</pub-id>
<pub-id pub-id-type="pmid">24065827</pub-id>
</element-citation>
</ref>
<ref id="B26-pharmaceuticals-12-00156">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cooper</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Halter</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Prosser</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Circadian rhythm and sleep-wake systems share the dynamic extracellular synaptic milieu</article-title>
<source/>Neurobiol. Sleep Circadian Rhythm.
          <year>2018</year>
<volume>5</volume>
<fpage>15</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1016/j.nbscr.2018.04.001</pub-id>
</element-citation>
</ref>
<ref id="B27-pharmaceuticals-12-00156">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacPhail</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Padnos</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Irons</surname>
<given-names>T.D.</given-names>
</name>
<name>
<surname>Padilla</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Locomotion in larval zebrafish: Influence of time of day, lighting and ethanol</article-title>
<source/>Neurotoxicology
          <year>2009</year>
<volume>30</volume>
<fpage>52</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuro.2008.09.011</pub-id>
<pub-id pub-id-type="pmid">18952124</pub-id>
</element-citation>
</ref>
<ref id="B28-pharmaceuticals-12-00156">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Umemoto</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Zebrafish as a systems toxicology model for developmental neurotoxicity testing</article-title>
<source/>Congenit. Anom.
          <year>2015</year>
<volume>55</volume>
<fpage>1</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1111/cga.12079</pub-id>
</element-citation>
</ref>
<ref id="B29-pharmaceuticals-12-00156">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venkatraman</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Edlow</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Immordino-Yang</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>The Brainstem in Emotion: A Review</article-title>
<source/>Front. Neuroanat.
          <year>2017</year>
<volume>11</volume>
<fpage>15</fpage>
<pub-id pub-id-type="doi">10.3389/fnana.2017.00015</pub-id>
<pub-id pub-id-type="pmid">28337130</pub-id>
</element-citation>
</ref>
<ref id="B30-pharmaceuticals-12-00156">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lecaudey</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Anselme</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Dildrop</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ruther</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Schneider-Maunoury</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Expression of the zebrafish Iroquois genes during early nervous system formation and patterning</article-title>
<source/>J. Comp. Neurol.
          <year>2005</year>
<volume>492</volume>
<fpage>289</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1002/cne.20765</pub-id>
<pub-id pub-id-type="pmid">16217788</pub-id>
</element-citation>
</ref>
<ref id="B31-pharmaceuticals-12-00156">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rzehak</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Covic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Saffery</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Reischl</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wahl</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grote</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xhonneux</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Langhendries</surname>
<given-names>J.P.</given-names>
</name>
<name>
<surname>Ferre</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>DNA-Methylation and Body Composition in Preschool Children: Epigenome-Wide-Analysis in the European Childhood Obesity Project (CHOP)-Study</article-title>
<source/>Sci. Rep.
          <year>2017</year>
<volume>7</volume>
<fpage>14349</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-13099-4</pub-id>
<pub-id pub-id-type="pmid">29084944</pub-id>
</element-citation>
</ref>
<ref id="B32-pharmaceuticals-12-00156">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Araujo</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Razolli</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Correa-da-Silva</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>De Lima-Junior</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Gaspar</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Sidarta-Oliveira</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Victorio</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Donato</surname>
<given-names>J.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.B.</given-names>
</name>
<name>
<surname>Velloso</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>The partial inhibition of hypothalamic IRX3 exacerbates obesity</article-title>
<source/>EBioMedicine
          <year>2019</year>
<volume>39</volume>
<fpage>448</fpage>
<lpage>460</lpage>
<pub-id pub-id-type="doi">10.1016/j.ebiom.2018.11.048</pub-id>
<pub-id pub-id-type="pmid">30522931</pub-id>
</element-citation>
</ref>
<ref id="B33-pharmaceuticals-12-00156">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lai</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Jabaudon</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Molyneaux</surname>
<given-names>B.J.</given-names>
</name>
<name>
<surname>Azim</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Arlotta</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Menezes</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Macklis</surname>
<given-names>J.D.</given-names>
</name>
</person-group>
<article-title>SOX5 controls the sequential generation of distinct corticofugal neuron subtypes</article-title>
<source/>Neuron
          <year>2008</year>
<volume>57</volume>
<fpage>232</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2007.12.023</pub-id>
<pub-id pub-id-type="pmid">18215621</pub-id>
</element-citation>
</ref>
<ref id="B34-pharmaceuticals-12-00156">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenfeld</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Ballif</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Torchia</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Sahoo</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ravnan</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lamb</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bejjani</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Shaffer</surname>
<given-names>L.G.</given-names>
</name>
</person-group>
<article-title>Copy number variations associated with autism spectrum disorders contribute to a spectrum of neurodevelopmental disorders</article-title>
<source/>Genet. Med.
          <year>2010</year>
<volume>12</volume>
<fpage>694</fpage>
<lpage>702</lpage>
<pub-id pub-id-type="doi">10.1097/GIM.0b013e3181f0c5f3</pub-id>
<pub-id pub-id-type="pmid">20808228</pub-id>
</element-citation>
</ref>
<ref id="B35-pharmaceuticals-12-00156">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamb</surname>
<given-names>A.N.</given-names>
</name>
<name>
<surname>Rosenfeld</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Neill</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Talkowski</surname>
<given-names>M.E.</given-names>
</name>
<name>
<surname>Blumenthal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Girirajan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Keelean-Fuller</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Pouncey</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Haploinsufficiency of SOX5 at 12p12.1 is associated with developmental delays with prominent language delay, behavior problems, and mild dysmorphic features</article-title>
<source/>Hum. Mutat.
          <year>2012</year>
<volume>33</volume>
<fpage>728</fpage>
<lpage>740</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22037</pub-id>
<pub-id pub-id-type="pmid">22290657</pub-id>
</element-citation>
</ref>
<ref id="B36-pharmaceuticals-12-00156">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Wedow</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Okbay</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Maghzian</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Zacher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Nguyen-Viet</surname>
<given-names>T.A.</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sidorenko</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Karlsson Linner</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals</article-title>
<source/>Nat. Genet.
          <year>2018</year>
<volume>50</volume>
<fpage>1112</fpage>
<lpage>1121</lpage>
<pub-id pub-id-type="doi">10.1038/s41588-018-0147-3</pub-id>
<pub-id pub-id-type="pmid">30038396</pub-id>
</element-citation>
</ref>
<ref id="B37-pharmaceuticals-12-00156">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Power</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Tansey</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Buttenschon</surname>
<given-names>H.N.</given-names>
</name>
<name>
<surname>Cohen-Woods</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bigdeli</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Kutalik</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Ripke</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steinberg</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide Association for Major Depression Through Age at Onset Stratification: Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium</article-title>
<source/>Biol. Psychiatry
          <year>2017</year>
<volume>81</volume>
<fpage>325</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.05.010</pub-id>
<pub-id pub-id-type="pmid">27519822</pub-id>
</element-citation>
</ref>
<ref id="B38-pharmaceuticals-12-00156">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lane</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Dashti</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Aragam</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Van Hees</surname>
<given-names>V.T.</given-names>
</name>
<name>
<surname>Strand</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Winsvold</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bowden</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Biological and clinical insights from genetics of insomnia symptoms</article-title>
<source/>Nat. Genet.
          <year>2019</year>
<volume>51</volume>
<fpage>387</fpage>
<lpage>393</lpage>
<pub-id pub-id-type="doi">10.1038/s41588-019-0361-7</pub-id>
<pub-id pub-id-type="pmid">30804566</pub-id>
</element-citation>
</ref>
<ref id="B39-pharmaceuticals-12-00156">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guthrie</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Patterning and axon guidance of cranial motor neurons</article-title>
<source/>Nat. Rev. Neurosci.
          <year>2007</year>
<volume>8</volume>
<fpage>859</fpage>
<lpage>871</lpage>
<pub-id pub-id-type="doi">10.1038/nrn2254</pub-id>
<pub-id pub-id-type="pmid">17948031</pub-id>
</element-citation>
</ref>
<ref id="B40-pharmaceuticals-12-00156">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasahara</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aoki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kiyono</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kagiwada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Mizoguchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goshima</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>EGF receptor kinase suppresses ciliogenesis through activation of USP8 deubiquitinase</article-title>
<source/>Nat. Commun.
          <year>2018</year>
<volume>9</volume>
<fpage>758</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-03117-y</pub-id>
<pub-id pub-id-type="pmid">29472535</pub-id>
</element-citation>
</ref>
<ref id="B41-pharmaceuticals-12-00156">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naert</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Vleminckx</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>CRISPR/Cas9 disease models in zebrafish and Xenopus: The genetic renaissance of fish and frogs</article-title>
<source/>Drug Discov. Today Technol.
          <year>2018</year>
<volume>28</volume>
<fpage>41</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/j.ddtec.2018.07.001</pub-id>
<pub-id pub-id-type="pmid">30205880</pub-id>
</element-citation>
</ref>
<ref id="B42-pharmaceuticals-12-00156">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Activation of Sterol Regulatory Element Binding Factors by Fenofibrate and Gemfibrozil Stimulates Myelination in Zebrafish</article-title>
<source/>Front. Pharmacol.
          <year>2016</year>
<volume>7</volume>
<fpage>206</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2016.00206</pub-id>
<pub-id pub-id-type="pmid">27462272</pub-id>
</element-citation>
</ref>
<ref id="B43-pharmaceuticals-12-00156">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cornet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Di Donato</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Terriente</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Combining Zebrafish and CRISPR/Cas9: Toward a More Efficient Drug Discovery Pipeline</article-title>
<source/>Front. Pharmacol.
          <year>2018</year>
<volume>9</volume>
<fpage>703</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2018.00703</pub-id>
<pub-id pub-id-type="pmid">30018554</pub-id>
</element-citation>
</ref>
<ref id="B44-pharmaceuticals-12-00156">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>What is the Thalamus in Zebrafish?</article-title>
<source/>Front. Neurosci.
          <year>2012</year>
<volume>6</volume>
<fpage>64</fpage>
<pub-id pub-id-type="doi">10.3389/fnins.2012.00064</pub-id>
<pub-id pub-id-type="pmid">22586363</pub-id>
</element-citation>
</ref>
<ref id="B45-pharmaceuticals-12-00156">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmidt</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Strähle</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Scholpp</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Neurogenesis in zebrafish—From embryo to adult</article-title>
<source/>Neural Dev.
          <year>2013</year>
<volume>8</volume>
<fpage>3</fpage>
<pub-id pub-id-type="doi">10.1186/1749-8104-8-3</pub-id>
<pub-id pub-id-type="pmid">23433260</pub-id>
</element-citation>
</ref>
<ref id="B46-pharmaceuticals-12-00156">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gunnarsson</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jauhiainen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kristiansson</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nerman</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Larsson</surname>
<given-names>D.G.</given-names>
</name>
</person-group>
<article-title>Evolutionary conservation of human drug targets in organisms used for environmental risk assessments</article-title>
<source/>Environ. Sci. Technol.
          <year>2008</year>
<volume>42</volume>
<fpage>5807</fpage>
<lpage>5813</lpage>
<pub-id pub-id-type="doi">10.1021/es8005173</pub-id>
<pub-id pub-id-type="pmid">18754513</pub-id>
</element-citation>
</ref>
<ref id="B47-pharmaceuticals-12-00156">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rihel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schier</surname>
<given-names>A.F.</given-names>
</name>
</person-group>
<article-title>Behavioral screening for neuroactive drugs in zebrafish</article-title>
<source/>Dev. Neurobiol.
          <year>2012</year>
<volume>72</volume>
<fpage>373</fpage>
<lpage>385</lpage>
<pub-id pub-id-type="doi">10.1002/dneu.20910</pub-id>
<pub-id pub-id-type="pmid">21567979</pub-id>
</element-citation>
</ref>
<ref id="B48-pharmaceuticals-12-00156">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perkins</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Ankley</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Crofton</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Garcia-Reyero</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>LaLone</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Tietge</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Villeneuve</surname>
<given-names>D.L.</given-names>
</name>
</person-group>
<article-title>Current perspectives on the use of alternative species in human health and ecological hazard assessments</article-title>
<source/>Environ. Health Perspect.
          <year>2013</year>
<volume>121</volume>
<fpage>1002</fpage>
<lpage>1010</lpage>
<pub-id pub-id-type="doi">10.1289/ehp.1306638</pub-id>
<pub-id pub-id-type="pmid">23771518</pub-id>
</element-citation>
</ref>
<ref id="B49-pharmaceuticals-12-00156">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>MacRae</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Zebrafish as tools for drug discovery</article-title>
<source/>Nat. Rev. Drug Discov.
          <year>2015</year>
<volume>14</volume>
<fpage>721</fpage>
<lpage>731</lpage>
<pub-id pub-id-type="doi">10.1038/nrd4627</pub-id>
<pub-id pub-id-type="pmid">26361349</pub-id>
</element-citation>
</ref>
<ref id="B50-pharmaceuticals-12-00156">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Koiwa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Using zebrafish in systems toxicology for developmental toxicity testing</article-title>
<source/>Congenit. Anom.
          <year>2016</year>
<volume>56</volume>
<fpage>18</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="doi">10.1111/cga.12142</pub-id>
</element-citation>
</ref>
<ref id="B51-pharmaceuticals-12-00156">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lam</surname>
<given-names>P.Y.</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>Developing zebrafish disease models for in vivo small molecule screens</article-title>
<source/>Curr. Opin. Chem. Biol.
          <year>2019</year>
<volume>50</volume>
<fpage>37</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1016/j.cbpa.2019.02.005</pub-id>
<pub-id pub-id-type="pmid">30928773</pub-id>
</element-citation>
</ref>
<ref id="B52-pharmaceuticals-12-00156">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barrett</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Wilhite</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Ledoux</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Evangelista</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I.F.</given-names>
</name>
<name>
<surname>Tomashevsky</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marshall</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Phillippy</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Holko</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NCBI GEO: Archive for functional genomics data sets–Update</article-title>
<source/>Nucleic Acids Res.
          <year>2013</year>
<volume>41</volume>
<fpage>D991</fpage>
<lpage>D995</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gks1193</pub-id>
<pub-id pub-id-type="pmid">23193258</pub-id>
</element-citation>
</ref>
<ref id="B53-pharmaceuticals-12-00156">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Breitling</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>McEntee</surname>
<given-names>C.W.</given-names>
</name>
<name>
<surname>Wittner</surname>
<given-names>B.S.</given-names>
</name>
<name>
<surname>Nemhauser</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Chory</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>RankProd: A bioconductor package for detecting differentially expressed genes in meta-analysis</article-title>
<source/>Bioinformatics
          <year>2006</year>
<volume>22</volume>
<fpage>2825</fpage>
<lpage>2827</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btl476</pub-id>
<pub-id pub-id-type="pmid">16982708</pub-id>
</element-citation>
</ref>
<ref id="B54-pharmaceuticals-12-00156">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gentleman</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Carey</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Bates</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Bolstad</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dettling</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Dudoit</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gautier</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gentry</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bioconductor: Open software development for computational biology and bioinformatics</article-title>
<source/>Genome Biol.
          <year>2004</year>
<volume>5</volume>
<fpage>R80</fpage>
<pub-id pub-id-type="doi">10.1186/gb-2004-5-10-r80</pub-id>
<pub-id pub-id-type="pmid">15461798</pub-id>
</element-citation>
</ref>
<ref id="B55-pharmaceuticals-12-00156">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hayakawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>E2F4 promotes neuronal regeneration and functional recovery after spinal cord injury in zebrafish</article-title>
<source/>Front. Pharmacol.
          <year>2016</year>
<volume>7</volume>
<fpage>119</fpage>
<pub-id pub-id-type="pmid">27242526</pub-id>
</element-citation>
</ref>
<ref id="B56-pharmaceuticals-12-00156">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sawada</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Comparative transcriptome analysis identifies CCDC80 as a novel gene associated with pulmonary arterial hypertension</article-title>
<source/>Front. Pharmacol.
          <year>2016</year>
<volume>7</volume>
<fpage>142</fpage>
<pub-id pub-id-type="pmid">27375481</pub-id>
</element-citation>
</ref>
<ref id="B57-pharmaceuticals-12-00156">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Downregulation of GSTK1 Is a Common Mechanism Underlying Hypertrophic Cardiomyopathy</article-title>
<source/>Front. Pharmacol.
          <year>2016</year>
<volume>7</volume>
<fpage>162</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2016.00162</pub-id>
<pub-id pub-id-type="pmid">27378925</pub-id>
</element-citation>
</ref>
<ref id="B58-pharmaceuticals-12-00156">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kotani</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Taimatsu</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ohga</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ota</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawahara</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Efficient Multiple Genome Modifications Induced by the crRNAs, tracrRNA and Cas9 Protein Complex in Zebrafish</article-title>
<source/>PLoS ONE
          <year>2015</year>
<volume>10</volume>
<elocation-id>e0128319</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0128319</pub-id>
<pub-id pub-id-type="pmid">26010089</pub-id>
</element-citation>
</ref>
<ref id="B59-pharmaceuticals-12-00156">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kawase</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Pharmacological profiling of zebrafish behavior using chemical and genetic classification of sleep-wake modifiers</article-title>
<source/>Front. Pharmacol.
          <year>2015</year>
<volume>6</volume>
<fpage>257</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2015.00257</pub-id>
<pub-id pub-id-type="pmid">26578964</pub-id>
</element-citation>
</ref>
<ref id="B60-pharmaceuticals-12-00156">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashikawa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Nishimura</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okabe</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuge</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Miyao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kawaguchi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sasagawa</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Potential protective function of the sterol regulatory element binding factor 1-fatty acid desaturase 1/2 axis in early-stage age-related macular degeneration</article-title>
<source/>Heliyon
          <year>2017</year>
<volume>3</volume>
<fpage>e00266</fpage>
<pub-id pub-id-type="doi">10.1016/j.heliyon.2017.e00266</pub-id>
<pub-id pub-id-type="pmid">28367511</pub-id>
</element-citation>
</ref>
<ref id="B61-pharmaceuticals-12-00156">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Thitamadee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Murata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kakinuma</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nabetani</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hirabayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hirate</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Okamoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bessho</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Canopy1, a positive feedback regulator of FGF signaling, controls progenitor cell clustering during Kupffer’s vesicle organogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2011</year>
<volume>108</volume>
<fpage>9881</fpage>
<lpage>9886</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1017248108</pub-id>
<pub-id pub-id-type="pmid">21628557</pub-id>
</element-citation>
</ref>
<ref id="B62-pharmaceuticals-12-00156">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thisse</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Thisse</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>In situ hybridization on whole-mount zebrafish embryos and young larvae</article-title>
<source/>Methods Mol. Biol.
          <year>2014</year>
<volume>1211</volume>
<fpage>53</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="pmid">25218376</pub-id>
</element-citation>
</ref>
<ref id="B63-pharmaceuticals-12-00156">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Langfelder</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Horvath</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>WGCNA: An R package for weighted correlation network analysis</article-title>
<source/>BMC Bioinf.
          <year>2008</year>
<volume>9</volume>
<elocation-id>559</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2105-9-559</pub-id>
<pub-id pub-id-type="pmid">19114008</pub-id>
</element-citation>
</ref>
<ref id="B64-pharmaceuticals-12-00156">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shannon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Markiel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ozier</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>N.S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Ramage</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Amin</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Schwikowski</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ideker</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Cytoscape: A software environment for integrated models of biomolecular interaction networks</article-title>
<source/>Genome Res.
          <year>2003</year>
<volume>13</volume>
<fpage>2498</fpage>
<lpage>2504</lpage>
<pub-id pub-id-type="doi">10.1101/gr.1239303</pub-id>
<pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="pharmaceuticals-12-00156-f001" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Venn diagrams of the number of differentially expressed genes regulated by Neurog1/2 and Ascl1. Transcriptome data of stem cells with and without overexpression of Neurog1/2 (GSE60548) or Ascl1 (GSE43971) were downloaded from a public database. Genes differentially expressed in stem cells on days 1, 3, and 4 post-induction of Neurog1/2 overexpression versus control cells, or on days 3 and 7 post-induction of Ascl1 overexpression versus control cells were identified using a false discovery rate threshold of 10%. The number of genes increased (<bold>A</bold>) and decreased (<bold>B</bold>) by Neurog1/2 or Ascl1 in each group and the overlap between groups are shown.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g001"></graphic>
</fig>
<fig id="pharmaceuticals-12-00156-f002" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Expression of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> in zebrafish. (<bold>A</bold>) qPCR analysis of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> expression in zebrafish at 1, 3, and 5 dpf. Data are presented as the mean ± SEM of n = 3 relative to <italic>actb</italic> mRNA. (<bold>B</bold>) Whole-mount in situ hybridization of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> expression in zebrafish at 3 dpf. Representative images of the lateral and dorsal views are shown. Scale bars, 200 μm.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g002"></graphic>
</fig>
<fig id="pharmaceuticals-12-00156-f003" orientation="portrait" position="float">
<label>Figure 3</label>
<caption>
<p>Generation of c3orf70-KO zebrafish. (<bold>A</bold>) Heteroduplex mobility assay of PCR products after amplification of the crRNA-targeted genomic region of <italic>c3orf70a</italic> and <italic>c3orf70b</italic>. Genomic DNA was extracted from c3orf70 wild-type (WT) and c3orf70-KO zebrafish and subjected to PCR to amplify short fragments of the <italic>c3orf70a</italic> and <italic>c3orf70b</italic> genes, including their crRNA target sites. The PCR products were electrophoresed in a 10% acrylamide gel. The positions of the expected homoduplexes for WT and KO zebrafish are indicated by black and red arrowheads, respectively. (<bold>B</bold>) Nucleotide sequence alignment of <italic>c3orf70a</italic> and <italic>c3orf70b</italic> genes from WT and KO zebrafish. The recognition sites of crRNA targeting <italic>c3orf70a</italic> and <italic>c3orf70b,</italic> including the PAM sequences, are shown in magenta and red boxes, respectively. (<bold>C</bold>) Alignment of amino acid sequences inferred from cDNA of c3orf70a and c3orf70b from WT and KO zebrafish.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g003"></graphic>
</fig>
<fig id="pharmaceuticals-12-00156-f004" orientation="portrait" position="float">
<label>Figure 4</label>
<caption>
<p>Impaired neuronal marker expression in c3orf70-KO zebrafish. (<bold>A</bold>–<bold>D</bold>) Whole-mount in situ hybridization (<bold>A</bold>,<bold>B</bold>) and qPCR (<bold>C</bold>,<bold>D</bold>) of <italic>neurod1</italic> (<bold>A</bold>,<bold>C</bold>) and <italic>elavl3</italic> (<bold>B</bold>,<bold>D</bold>) expression in c3orf70 WT and KO zebrafish at 2 dpf. Data are presented as the mean ± SEM of <italic>n</italic> = 4 for both WT and KO. (<bold>E</bold>,<bold>F</bold>) Representative images (<bold>E</bold>) and quantification of fluorescence (<bold>F</bold>) in Tg (eno2: Cerulean) c3orf70-WT or KO zebrafish at 5 dpf. Data are presented as the mean ± SEM of <italic>n</italic> = 60 and 62 for WT and KO groups, respectively.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g004"></graphic>
</fig>
<fig id="pharmaceuticals-12-00156-f005" orientation="portrait" position="float">
<label>Figure 5</label>
<caption>
<p>Weighted gene coexpression network analysis (WGCNA) identifies <italic>IRX3</italic> as a gene coexpressed with C3orf70 during neurogenesis. (<bold>A</bold>) Schematic showing the 31 genes coexpressed with <italic>C3orf70</italic> in human stem cells overexpressing Neurog1/2 (GSE60548) [<xref ref-type="bibr" rid="B13-pharmaceuticals-12-00156">13</xref>] and mouse stem cells overexpressing Ascl1 (GSE43971) [<xref ref-type="bibr" rid="B12-pharmaceuticals-12-00156">12</xref>], as identified by WGCNA. <italic>IRX3</italic> and <italic>SOX5</italic> are outlined in red. (<bold>B</bold>) qPCR analysis of <italic>irx3b</italic> expression in c3orf70-WT and KO zebrafish. Data are presented as the mean ± SEM of <italic>n</italic> = 3.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g005"></graphic>
</fig>
<fig id="pharmaceuticals-12-00156-f006" orientation="portrait" position="float">
<label>Figure 6</label>
<caption>
<p>Impaired circadian behavior in c3orf70-KO zebrafish. (<bold>A</bold>) Overview of the circadian behavioral analysis. Behavior was assessed on 7 to 8 dpf using four endpoints: distance moved (<bold>B</bold>,<bold>F</bold>), cumulative duration at high mobility (<bold>C</bold>,<bold>G</bold>) and medium mobility (<bold>D</bold>,<bold>H</bold>), and cumulative duration in the center zone (<bold>E</bold>,<bold>I</bold>). Behavior during the dark and light periods is shown in (<bold>B</bold>–<bold>E</bold>) and (<bold>F</bold>–<bold>I)</bold>, respectively. Data are presented as the mean ± SEM of <italic>n</italic> = 40 for WT and <italic>n</italic> = 41 for KO.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g006"></graphic>
</fig>
<fig id="pharmaceuticals-12-00156-f007" orientation="portrait" position="float">
<label>Figure 7</label>
<caption>
<p>Impaired behavioral responses to light–dark cycling in c3orf70-KO zebrafish. (<bold>A</bold>) Overview of the behavioral analysis of the response to 3-min cycling between light and dark conditions. Behavior in c3orf70-WT or KO was assessed as: distance moved (<bold>B</bold>,<bold>F</bold>), cumulative duration at high mobility (<bold>C</bold>,<bold>G</bold>) and medium mobility (<bold>D</bold>,<bold>H</bold>), and cumulative duration in the center zone (<bold>E</bold>,<bold>I</bold>). Behavior during dark and light periods is shown in (<bold>B</bold>–<bold>E</bold>) and (<bold>F</bold>–<bold>I</bold>), respectively. Data are presented as the mean ± SEM of <italic>n</italic> = 40 for WT and <italic>n</italic> = 41 for KO.</p>
</caption>
<graphic xlink:href="pharmaceuticals-12-00156-g007"></graphic>
</fig>
<table-wrap id="pharmaceuticals-12-00156-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">pharmaceuticals-12-00156-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Differentially expressed genes regulated by Neugog1/2 and Ascl1.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="2" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Symbol</th>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Neurog1/2 Day 1</th>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Neurog1/2 Day 3</th>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Neurog1/2 Day 4</th>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ascl1 Day 3</th>
<th align="center" colspan="2" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Ascl1 Day 7</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FC</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FDR</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FC</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FDR</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FC</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FDR</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FC</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FDR</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FC</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>C3orf70</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8.13 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.761 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">24.41 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.11 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">23.27 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.91 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.54 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.67 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CHGB</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.80 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.97 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">12.25 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.08 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">14.02 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.98 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.89 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.21 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>CHRNA3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">26.20 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.17 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">23.90 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.13 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">39.49 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.76 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.72 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.30 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>DCX</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11.89 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.22 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">38.49 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.20 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">102.50 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">9.74 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.91 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">0.0000</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>EBF2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">90.33 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.33 × 10<sup>−5</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">24.69 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.08 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">37.51 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">8.50 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.84 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.51 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ELAVL3</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">100.60 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">9.81 × 10<sup>−6</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">360.60 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.26 × 10<sup>−6</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">509.80 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">8.26 × 10<sup>−6</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.50 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.38 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ELAVL4</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">10.17 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.78 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">100.80 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">5.48 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">172.60 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.61 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.62 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.85 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>GFRA1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">40.96 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">5.87 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">54.30 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.23 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">120.00 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">6.45 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.65 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.44 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>INSM1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">222.40 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.23 × 10<sup>−7</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">290.70 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.35 × 10<sup>−5</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">461.80 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.47 × 10<sup>−5</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.50 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.42 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ISL1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">24.59 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.51 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">97.31 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">5.67 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">227.50 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.15 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.59 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">5.34 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MDGA1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">110.60 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.84 × 10<sup>−6</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">291.10 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.54 × 10<sup>−6</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">224.50 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">4.52 × 10<sup>−5</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.54 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">6.46 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>MYT1</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">5.63 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">5.69 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">45.99 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.05 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">74.14 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.16 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.09 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.05 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>ONECUT2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">11.57 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.27 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">85.82 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.27 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">112.50 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.48 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.48 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">8.22 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>PCDH9</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">8.05 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.91 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">79.33 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">9.67 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">94.84 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.24 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.49 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">7.73 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
<italic>POU3F2</italic>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">38.74 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">6.63 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">256.10 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">2.35 × 10<sup>−5</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">189.20 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.85 × 10<sup>−4</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">1.70 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">3.55 × 10<sup>−2</sup></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
<italic>ROBO2</italic>
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">12.58 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.05 × 10<sup>−2</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">27.02 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">9.23 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">73.36 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">2.16 × 10<sup>−3</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">1.49 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">7.67 × 10<sup>−2</sup></td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>